Boehringer Ingelheim· @Boehringer · X·· 2026-02-26AI 评分40
AI 导读
#NEWS：我们正在引进Sitryx的临床前项目，靶向驱动疾病的免疫通路——为我们的免疫学管线增添一种潜在的首创口服精准疗法。 了解更多：https://go.boehringer.com/5GGK #DrugDevelopment #PrecisionMedicine #Immunology
正文
#NEWS: We are licensing Sitryx’s preclinical program targeting disease‑driving immune pathways - adding a potential first‑in‑class, oral precision therapy approach to our immunology pipeline.
Learn more: https://go.boehringer.com/5GGK
#DrugDevelopment #PrecisionMedicine #Immunology
来源：Boehringer Ingelheim · x.com